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Beneficiaries With Stage IV Breast Cancer
Devon K. Check, Cleo A. Samuel, Donald L. Rosenstein, and Stacie B. Dusetzina
A B S T R A C T
Purpose
Early supportive caremay improve quality of life and end-of-life care among patients with cancer.We
assessed racial disparities in early use of medications for common cancer symptoms (depression,
anxiety, insomnia) and whether these potential disparities modify end-of-life care.
Methods
We used 2007 to 2012 SEER-Medicare data to evaluate use of supportive medications (opioid pain
medications and nonopioid psychotropics, including antidepressants/anxiolytics and sleep aids) in
the 90 days postdiagnosis among black and white women with stage IV breast cancer who died
between 2007 and 2012. We used modified Poisson regression to assess the relationship between
race and supportive treatment use and end-of-life care (hospice, intensive care unit, more than one
emergency department visit or hospitalization 30 days before death, in-hospital death).
Results
The study included 752 white and 131 black women. We observed disparities in nonopioid psy-
chotropic use between black andwhite women (adjusted risk ratio [aRR], 0.51; 95%CI, 0.35 to 0.74)
but not in opioid pain medication use. There were also disparities in hospice use (aRR, 0.86; 95%CI,
0.74 to 0.99), intensive care unit admission or more than one emergency department visit or
hospitalization 30 days before death (aRR, 1.28; 95% CI, 1.01 to 1.63), and risk of dying in the
hospital (aRR, 1.59; 95% CI, 1.22 to 2.09). Supportive medication use did not attenuate end-of-life
care disparities.
Conclusion
We observed racial disparities in early supportive medication use among patients with stage IV
breast cancer. Although they did not clearly attenuate end-of-life care disparities, medication use
disparitiesmay be of concern if they point to disparities in adequacy of symptommanagement given
the potential implications for quality of life.
J Clin Oncol 34:2265-2270. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Cancer and its treatment are associated with
a range of physiologic and psychosocial symp-
toms.1-7 Research suggests that minority patients
with cancer may receive inadequate symptom
management. Studies have documented racial/
ethnic disparities in outcomes related to symp-
tom burden and severity,8,9 adequacy of pain
treatment,10-12 and patients’ perceived unmet
need for supportive services, including psycho-
logic services.13 Disparities persist even as sup-
portive care is increasingly recognized as a vital
component of high-quality cancer care.14,15
Adequacy of cancer-related symptom control
has important implications for patients’ quality of
life (QOL) and well-being.3,14-21 Data from a ran-
domized controlled trial suggested that early use of
supportive care may influence health care use at the
end of life. Specifically, patients who received early
supportive care integrated with standard oncologic
care were less likely than patients who received
standard oncologic care alone to receive chemo-
therapy within 14 days of death and were more
likely to transition to hospice before death.22 One
plausible hypothesis for the relationship among
early palliative care, hospice use, and less-intensive
end-of-life care is that in providing decisional
support, supportive/palliative care providers may
© 2016 by American Society of Clinical Oncology 2265
VOLUME 34 • NUMBER 19 • JULY 1, 2016
assist both oncologists and patients in planning for the end of life.
Such discussionsmay facilitate the transition from active treatment to
hospice services and improve the quality of end-of-life care.22
Several studies have demonstrated that black patients are less
likely than white patients to use hospice,23 which has been linked
with enhanced patient and caregiver QOL,24,25 prolonged survival,26,27
and increased concordance with patients’ preferred place of death.28,29
Studies have also demonstrated that black patients are more likely
to receive intensive interventions at the end of life,30 which are of
questionable benefit in terms of lengthening life of patients with
terminal illness, and may be detrimental to patients’ QOL.24,31
Early integration of supportive care services may be a promising
strategy for improving patients’QOL as well as the quality of their care
at the end of life. The objectives of this study were twofold. Within
a cohort of patients with stage IV breast cancer who died during the
study period, we explored early use of medications to treat common
breast cancer symptoms (pain, depression/anxiety, and insomnia) and
assessed whether use varied by race. Second, we evaluated racial
disparities in hospice use and end-of-life care measures and examined
the role of supportive medication use in attenuating potential racial
disparities in end-of-life care, should they exist.
METHODS
Data Source
Weused theNational Cancer Institute SEERdatabase linkedwithMedicare
fee-for-service claims from 2006 to 2012. The SEER program consists of
population-based cancer registries and represents 28% of the population with
cancer. SEER data are merged withMedicare claims data of patients age 65 years
and older and then linked with the National Death Index to obtain date and
cause of death.32 This study was conducted in accordance with a SEER-Medicare
data use agreement and received exemption from the institutional review board
at the University of North Carolina at Chapel Hill.
Cohort
We identified patients with a first diagnosis of breast cancer during
2007 to 2011 who were age 65 years or older and who were alive at diagnosis
and not missing month of diagnosis (n = 104,629). We further excluded
those not continuously enrolled in fee-for-service Medicare Parts A and B for
6 months before and 3 months after diagnosis (n = 40,875). We excluded
patients who were not enrolled in a stand-alone Medicare Part D plan for
3 months before and after diagnosis (n = 30,105) as well as men (n = 263)
and women with end-stage renal disease (n = 220). Finally, we excluded
womenwith stage 0 to III disease (n = 31,767), those without a recorded date
of death (n = 321), those who died within 90 days after diagnosis (n = 108),
and those enrolled in a health maintenance organization in the 3 months
before death (n = 23). The study was limited to womenwith stage IV disease
at initial diagnosis because SEER does not contain information about disease
recurrence. Furthermore, because of the small proportion of nonblack
minorities in the sample (n = 64), we restricted the study to black and white
patients. The final cohort comprised 883 decedents.
Outcomes
Supportive Treatment Use. We assessed patients’ use of supportive
medications, including opioid pain medications and nonopioid psycho-
tropic medications (antidepressants and nonbenzodiazepine sleep aids)
within 90 days after cancer diagnosis. We measured any use of supportive
medications and use of each category of medications (opioid pain med-
ications and nonopioid psychotropics). We were unable to capture ben-
zodiazepines, which were not covered by Medicare Part D until 2013. A
complete list of included medications is provided in the Appendix Table A1
(online only). We selected these treatments as a potential claims-based
indicator for patients’ engagement with supportive care with the hypothesis
that patients who received symptomatic treatment early in the course of the
postdiagnosis period were more likely to receive comprehensive supportive
care, including end-of-life care planning, later in the care trajectory.
End-of-Life Care. We created indicators of four end-of-life care
measures that were based on those developed and measured in admin-
istrative data.33,34 These were hospice use before death (both any use and
use of # 3 days among users), in-hospital death, receipt of chemotherapy
within 14 days of death, and high-cost health care utilization (intensive
care unit [ICU] admission, more than one emergency department [ED]
visit, more than one hospitalization) in the last 30 days of life. We created
a composite indicator of occurrence of any of these three outcomes because
each individual outcome was relatively rare in the present sample.
Independent Variable
The main independent variable in the analysis was race (black or
white) as reported in the SEER-Medicare data.
Covariates
Covariates were age and marital status at diagnosis; year of diagnosis;
US region; the extent of urbanization at patients’ residences (obtained from
the Area Resource File); and 2000 census tract–level measures of socio-
economic status (SES), including high school completion rate and median
income. We assessed comorbid illness by using the Klabunde modification
of the Charlson comorbidity index.35 Cancer-directed treatment (surgery,
radiation, chemotherapy, endocrine therapy) was identified by using in-
patient, outpatient, and pharmacy claims. We also controlled for patients’
history of any inpatient or outpatient mental health diagnosis (International
Classification of Diseases, Ninth Revision, codes 290.0 to 319.99) and prior
use of supportive medications.
Statistical Analysis
We examined the distribution of patient characteristics, supportive
medication use, and end-of-life care between racial groups by using x2 tests
for categorical variables and t tests for continuous variables. We used modified
Poisson regression36 to assess the relationship between race and receipt of early
supportive medications and end-of-life care by controlling for relevant patient
characteristics. Indicators of supportivemedication use and interactions of race
and supportive medication use were then added to the end-of-life caremodels.
We present adjusted risks and adjusted risk ratios (aRRs) with 95% CIs.
Accounting for SES
The Institute of Medicine defines racial health care disparities as
differences in treatment not justified by differences in health status or
preferences.37 Analytically, this definition of disparities controls for dif-
ferences in health status and, if available, preferences for care but rec-
ognizes the mediating role of SES and SES-related factors and excludes
these from the model. This approach acknowledges that adjusting for SES-
related factors may mask the effect of race on care.38-40
In accordance with the Institute of Medicine definition of health care
disparities, our primary models adjusted for clinical characteristics,
namely age, year of cancer diagnosis, medical comorbidity, and receipt of
cancer-directed therapy. The supportive medication models also included
indicators of mental health and supportive medication use history. We did
not adjust for census tract–level measures of SES in the primary models.
We also did not adjust for other potential mediators of disparities, namely
geographic factors (US region of residence and metropolitan versus
nonmetropolitan residence) and marital status.40 However, because an
understanding of where disparities in care might arise is important, we
conducted sensitivity analyses to assess whether differences in census
tract–level SES, marital status, or geography attenuated observed dis-
parities in supportive medication use and end-of-life care.
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Finally, we conducted additional sensitivity analyses that limited the
sample to womenwho died as a result of breast cancer because womenwith
rapidly progressing cancer may have supportive care needs and experiences
that are distinct from women with competing health concerns.
RESULTS
The sample included 883 women (85.2% white, 14.8% black).
Clinical and demographic characteristics of the study sample by
race are shown in Table 1. Black women had a higher comorbidity
burden and were more likely to be single and to have a lower SES
than white women. All women had similar patterns of cancer-
directed therapy. With regard to prior supportive treatment use, no
difference was found in prediagnosis use of opioids (22.1 v 22.7 for
black and white women, respectively), but black women were
significantly less likely to have used nonopioid psychotropics in the
months preceding a breast cancer diagnosis (13% v 23%).
Bivariate Analysis
Unadjusted analyses did not reveal statistically significant
racial differences in women’s early use of any supportive medi-
cations (Table 2). Within specific medication groups, black women
were as likely as white women to receive opioid pain medications;
however, they were half as likely to receive nonopioid psycho-
tropics (32% white, 16% black; P , .001).
Racial differences also were found in hospice use, with black
women 11% less likely to use hospice than white women (risk of
hospice use, 71%white, 60% black; P,.05; Table 3). Black women
were also 16% more likely to die in the hospital (risk of terminal
hospitalization, 22% white, 36% black; P , .001) and 11% more
likely to have an ICU admission or more than one hospitalization
or ED visit in the final 30 days of life (risk of admission, 29% white,
40% black; P , .05). Because few women in the sample received
chemotherapy in the last 14 days of life or entered hospice within
3 days of death, we excluded these outcomes from the final models.
Primary Analysis
In the primary models that adjusted for clinical character-
istics, racial differences in any supportive medication use, and use
of opioid pain medications remained insignificant. However,
disparities in use of nonopioid psychotropic medications persisted,
with black women having a 44% decreased risk of using these
medications (aRR, 0.56; 95% CI, 0.39 to 0.80). The results of the
adjusted medication use models are shown in Table 2.
We also observed racial disparities in end-of-life care. Blackwomen
had a 60% increased risk of dying in the hospital (aRR, 1.60; 95% CI,
1.22 to 2.09) and a 14% decreased risk of entering hospice (aRR, 0.86;
95% CI, 0.74 to 0.99). The relationship between race and risk of having
an ICU admission or more than one ED visit or hospitalization in the
last 30 days of life was also significant after adjustment, with black
women having a 30% increased risk of use of these services (aRR, 1.30;
95% CI, 1.02 to 1.65). The results of the adjusted end-of-life care
models are shown in Table 3. In adjusted (and unadjusted) models, use
of nonopioid psychotropicmedications was not statistically significantly
associated with hospice use, dying in the hospital, or health care uti-
lization in the last 30 days of life overall or by racial subgroup (Table 4).
Sensitivity Analyses
In models that adjusted for census tract–level measures of SES
and indicators of marital status and geographic location in addition
to clinical characteristics, racial disparities in the use of supportive
medications were similar to those demonstrated in the primary
Table 1. Clinical and Demographic Characteristics of Sample by Race
Characteristic White (%) Black (%) P
No. of patients 752 131
Demographic characteristic
Age at cancer diagnosis .05
65-70 years 24 33
71-76 years 23 28
77-82 years 24 21
$ 83 years 30 20
Marital status at diagnosis
Married/partnered 27 8 < .001
Nonmarried/partnered 69 82
Unknown 4 9
Median household income
in census tract of residence
$5,299-$26,469 21 49 < .001
$26,470-$36,165 26 23
$36,166-$50,838 — —
$50,839-$200,014 28 —
Unknown — 0
Proportion of residents with
no high school degree in
census tract of residence
0.53-8.88 28 — < .001
8.89-15.91 27 15
15.92-27.06 — —
27.07-79.92 21 49
Unknown — 0
Residence
Metropolitan county 79 87 .04
Nonmetropolitan county 21 13
US region
Northeast 28 18 < .001
Midwest 16 14
West 32 22
South 25 47
Clinical characteristic
Year of cancer diagnosis
2007 24 22 .82
2008 21 22
2009 22 19
2010 17 21
2011 16 16
Charlson comorbidity index
0 73 63 .03
1 19 22
$ 2 8 15
Cancer treatment (any), % yes 85 84 .74
Surgery 25 22 .46
Radiation 35 33 .65
Chemotherapy 45 39 .20
Endocrine therapy 61 58 .51
Previous mental health
diagnosis, % yes
18 15 .39
Previous supportive
medication use (any), % yes
37 29 .08
Previous opioid use, % yes 23 22 .88
Previous nonopioid
psychotropic use, % yes
23 13 .02
NOTE. Values in bold are statistically significant. Percentages that reflect counts
, 11 and percentages that would allow counts, 11 to be derived by using other
information in the table were suppressed (—) to protect patient identity.
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models (data not shown). Racial disparities in end-of-life care were
also consistent with those demonstrated in the primary models,
although the relationships between race and risk of hospice use and
risk of having an ICU admission or more than one ED visit or
hospitalization became marginally statistically significant.
In an analysis restricted to women who died as a result of
breast cancer (n = 607), disparities in supportive medication use
were again similar to those demonstrated in the primary models.
The disparity in risk of hospice use did not persist in this restricted
sample, and the relationship between race and risk of having an
ICU admission or more than one ED visit or hospitalization was
marginally statistically significant. Of the 276 women in the sample
who did not have breast cancer recorded as the cause of death,
nearly one half (n = 131) did not have another cause of death
recorded. Among those who did, diseases of the heart (n = 37) and
miscellaneous malignant cancer (n = 23) were most common.
DISCUSSION
In the primary analyses, we observed no racial disparities in
women’s early use of any supportive medications or opioid pain
medications. However, we did find a racial disparity in women’s use
of nonopioid psychotropic medications to treat depression, anx-
iety, and insomnia. Specifically, compared with similar white
women, black women had a 44% decreased risk of using these
medications. We also observed disparities in end-of-life care. Black
women were at decreased risk of entering hospice and increased
risk of having an ICU admission or more than one ED visit or
hospitalization in the last 30 days of life and of dying in the
hospital. Use of nonopioid psychotropics was not associated with
end-of-life care measures; thus, it does not seem to mediate the
observed relationship between race and end-of-life care.
This study is the first to our knowledge to demonstrate po-
tential disparities in the use of supportive medications for treat-
ment of common symptoms of cancer, namely depression, anxiety,
and insomnia, although others have demonstrated racial disparities
in self-reported unmet supportive care needs.13 Potential dispar-
ities in use of medications to treat cancer-related symptomsmay be
attributable to cost-related barriers.41 However, the addition of SES
variables to the present medication use models did not attenuate
disparities in nonopioid psychotropic use. This may be due to
potential misclassification of individual-level SES from using area-
level SES measures, which often capture complementary contex-
tual dimensions of SES.42,43 An alternative explanation for the lack
of effect of SES on disparities in nonopioid psychotropic medi-
cation use is that observed disparities are not purely related to the
cost of medications. Previous research on disparities in use of
mental health services suggested that lower use of services among
minorities may be due to cultural or attitudinal factors around
mental health.44-46 Still, minorities’ lower access to general and
specialty care are likely to contribute to disparities in cancer
symptom management.47
Suboptimal pain treatment among minorities has been
demonstrated consistently in previous studies and has been partly
explained by cultural differences in pain-related attitudes.
Table 2. Unadjusted and Adjusted Associations of Race With Supportive Medication Use
Supportive Medication Use
Risk (95% CI) Risk Ratio (95% CI)
Unadjusted Adjusted Black v White
White Black White Black Unadjusted Adjusted
Any supportive medications 0.69 (0.66 to 0.73) 0.64 (0.56 to 0.73) 0.49 (0.42 to 0.58) 0.46 (0.39 to 0.56) 0.93 (0.81 to 1.06) 0.94 (0.83 to 1.07)
Opioid pain medications 0.61 (0.57 to 0.64) 0.60 (0.52 to 0.69) 0.45 (0.36 to 0.56) 0.47 (0.38 to 0.57) 0.98 (0.84 to 1.14) 0.97 (0.84 to 1.13)
Nonopioid psychotropic medications 0.32 (0.28 to 0.35) 0.16 (0.11 to 0.24) 0.32 (0.11 to 0.90) 0.18 (0.06 to 0.51) 0.51 (0.34 to 0.76) 0.56 (0.39 to 0.80)
NOTE. Risks for black and white patients were calculated at the reference values of the covariates, which were as follows for each covariate: age ($ 83 years), year of
cancer diagnosis (2011), cancer treatment received (none received), comorbidity score ($ 2), previous mental health diagnosis (no diagnosis), and previous use of
supportive medications (no use). Risk ratios in bold are statistically significant. The following covariates were included in the adjusted models: age, marital status, year
of cancer diagnosis, cancer treatment received, comorbidity score, previous mental health diagnosis, and previous use of supportive medications.
Table 3. Unadjusted and Adjusted Associations of Race With End-of-Life Care Measures
End-of-Life Care Measure
Risk (95% CI) Risk Ratio (95% CI)
Unadjusted Adjusted Black v White
White Black White Black Unadjusted Adjusted
Any hospice use 0.71 (0.68 to 0.74) 0.60 (0.52 to 0.69) 0.44 (0.27 to 0.73) 0.38 (0.23 to 0.62) 0.85 (0.73 to 0.98) 0.86 (0.74 to 0.99)
Terminal hospitalization 0.22 (0.19 to 0.25) 0.36 (0.29 to 0.45) 0.27 (0.17 to 0.43) 0.43 (0.27 to 0.68) 1.63 (1.25 to 2.12) 1.60 (1.22 to 2.09)
ICU admission, more than one ED visit,
or more than one hospitalization in
last 30 days of life
0.29 (0.26 to 0.32) 0.40 (0.32 to 0.49) 0.28 (0.20 to 0.37) 0.36 (0.26 to 0.50) 1.38 (1.08 to 1.75) 1.30 (1.02 to 1.65)
NOTE. Risks for black and white patients were calculated at the reference values of the covariates, which were as follows for each covariate: age ($ 83 years), year of
cancer diagnosis (2011), cancer treatment received (none received), comorbidity score ($ 2), previous mental health diagnosis (no diagnosis), and previous use of
supportive medications (no use). Estimated risk ratios in bold are statistically significant. The following covariates were included in the adjusted models: age, marital
status, year of cancer diagnosis, cancer treatment received, and comorbidity score.
Abbreviations: ED, emergency department; ICU, intensive care unit.
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Physician-related factors, including underestimation of minority
patients’ pain and beliefs about minority groups, also contribute to
disparities in pain treatment.47 Of note, we did not observe a racial
disparity in use of opioid pain medications in the present sample.
Several possible reasons exist for the seeming inconsistency of our
findings with previous research. First, we measured pain treatment
as a binary indicator of any opioid pain medication use. Other
studies of disparities in analgesic use have used more-nuanced
measures of pain management that capture the appropriateness of
prescribed drugs and dosing and patient adherence.48-50 Second,
many studies of disparities in cancer pain management have used
patients’ symptom reports rather than or in addition to an ex-
amination of medication use.50-52 Thus, the lack of disparity in
opioid use in the present study is not necessarily indicative of a lack
of disparity in adequacy of pain management; however, the data
were not sufficient to capture the latter outcome.
All of the present analyses revealed that black women were
more likely to die in the hospital. This finding is consistent with
previous research on racial disparities in end-of-life care.53 We also
found that black women were less likely to use hospice and more
likely to have an ICU admission or more than one ED visit or
hospitalization in the 30 days before death. However, these findings
were inconsistent across primary and sensitivity analyses. Sup-
portive medication use did not attenuate observed end-of-life care
disparities possibly because pharmacologic symptommanagement
is an insufficient indicator of patients’ engagement with supportive
care. The single outpatient palliative care intervention to date that
has demonstrated an effect on end-of-life care consisted of mul-
tiple components, including symptom management, patient and
family coping, and illness understanding and education.19,54 This
prior intervention, however, was tested among patients with ad-
vanced lung cancer, which has a different prognosis and trajectory
than advanced breast cancer. An alternative explanation is that
disparities in risk of hospice use and dying in the hospital may be
explained by factors other than early use of supportive care. For
example, black and white patients may have differential preferences
for end-of-life care, including intensity of care during the period
immediately preceding death.30
This study had several limitations. First, it focused on black
and white patients with stage IV breast cancer who received fee-for-
service Medicare and Medicare Part D coverage. It is unclear
whether the results extend to other populations of patients with
cancer. Second, the measurement of receipt of supportive cancer
care by using claims data can be challenging because some im-
portant aspects of supportive care (eg, counseling, decision sup-
port) may be undercoded. We attempted to measure supportive
care by using a binary indicator of supportive medication use, but
this may have been insufficient because pharmacologic symptom
management is just one aspect of supportive care. Third, similar
studies that focus on decedents (versus patients who are dying)
may be subject to bias, which results from subject selection and
time period.55 Finally, we were unable to account for patient
preferences for supportive medication use and end-of-life care,
which, as in previous research, may differ between black and white
patients. Thus, the present analyses may be subject to unmeasured
confounding. These limitations notwithstanding, we present novel
observational data on the use of supportive care services among
patients with stage IV breast cancer that may point to important
gaps in receipt of these services.
In conclusion, we found evidence of racial disparities in the
use of some supportive medications and in patterns of end-of-life
care. Although the results do not suggest that supportive medi-
cations attenuate disparities in end-of-life care, disparities in
supportive medication use may be of concern regardless of their
effect on end-of-life outcomes, if they point to disparities in ad-
equacy of symptom management, given the potential implications
for QOL. To determine whether disparities in medication use
indicate disparities in care quality, future research should include
data on patients’ supportive care needs and preferences around
medication use.
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Appendix
Table A1. Generic Names of Medications Included in Analysis
Supportive Medication Category Generic Drug Name
Opioid pain medications Buprenorphine
Fentanyl
Hydrocodone
Hydromorphone
Levorphanol
Meperidine
Methadone
Morphine
Nalbuphine
Oxycodone
Oxymorphone
Propoxyphene
Tapentadol
Tramadol
Nonopioid psychotropic medications
Antidepressants Amitriptyline
Amoxapine
Bupropion
Citalopram
Clomipramine
Desipramine
Desvenlafaxine
Doxepin
Duloxetine
Escitalopram
Fluoxetine
Fluvoxamine
Imipramine
Isocarboxazid
Maprotiline
Milnacipran
Mirtazapine
Nefazodone
Nortriptyline
Paroxetine
Phenelzine
Protriptyline
Sertraline
Tranylcypromine
Trazodone
Trimipramine
Venlafaxine
Vilazodone
Nonbenzodiazepine sleep aid Buspirone
Eszopiclone
Hydroxyzine
Pregabalin
Zaleplon
Zolpidem
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